{"slug":"early-phase","tag":"early-phase","variants":["early-phase"],"description":"No description yet","count":7,"kinds":{"person":7},"related":[{"slug":"trialist","tag":"trialist","shared":2},{"slug":"adjuvant","tag":"adjuvant","shared":1},{"slug":"aml","tag":"aml","shared":1},{"slug":"breast","tag":"breast","shared":1},{"slug":"drug-development","tag":"drug development","shared":1},{"slug":"endocrine","tag":"endocrine","shared":1},{"slug":"idh","tag":"idh","shared":1},{"slug":"melanoma","tag":"melanoma","shared":1},{"slug":"menin","tag":"menin","shared":1},{"slug":"n-of-1","tag":"n-of-1","shared":1},{"slug":"pancreatic","tag":"pancreatic","shared":1},{"slug":"precision-oncology","tag":"precision oncology","shared":1}],"records":[{"id":"komal-jhaveri","kind":"person","name":"Komal Jhaveri","route":"/people/komal-jhaveri/","tldr":"Leads the next wave of endocrine therapy: oral SERDs like imlunestrant and the PI3K inhibitor inavolisib."},{"id":"daniel-von-hoff","kind":"person","name":"Daniel D. Von Hoff","route":"/people/daniel-von-hoff/","tldr":"Led the MPACT trial of nab-paclitaxel plus gemcitabine and has run more first-in-human cancer trials than almost anyone."},{"id":"jason-luke","kind":"person","name":"Jason J. Luke","route":"/people/jason-luke/","tldr":"Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma."},{"id":"eytan-stein","kind":"person","name":"Eytan M. Stein","route":"/people/eytan-stein/","tldr":"Led the enasidenib and revumenib trials that brought IDH2 and menin inhibitors to acute leukaemia."},{"id":"razelle-kurzrock","kind":"person","name":"Razelle Kurzrock","route":"/people/razelle-kurzrock/","tldr":"Precision oncology pioneer who showed that matching drugs to each patient's mutations, in combination, improves outcomes."},{"id":"vivek-subbiah","kind":"person","name":"Vivek Subbiah","route":"/people/vivek-subbiah/","tldr":"Early-phase trialist who led the study showing dabrafenib and trametinib work in BRAF-mutant anaplastic thyroid cancer, the first approved treatment for that disease, and many of the RET inhibitor trials."},{"id":"antoine-italiano","kind":"person","name":"Antoine Italiano","route":"/people/antoine-italiano/","tldr":"Bordeaux oncologist who led CABONE, the trial that showed cabozantinib shrinks or stabilises osteosarcoma and Ewing sarcoma after standard treatment has failed."}]}